Cargando…
Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer
BACKGROUND: Pancreatic cancer is one of the most lethal tumors. The aim of this study is to provide an effective therapeutic discovery platform for pancreatic cancer by establishing and characterizing patient-derived organoids (PDOs). METHODS: PDOs were established from pancreatic tumor surgical spe...
Autores principales: | Watanabe, Sadanori, Yogo, Akitada, Otsubo, Tsuguteru, Umehara, Hiroki, Oishi, Jun, Kodo, Toru, Masui, Toshihiko, Takaishi, Shigeo, Seno, Hiroshi, Uemoto, Shinji, Hatano, Etsuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063137/ https://www.ncbi.nlm.nih.gov/pubmed/35505283 http://dx.doi.org/10.1186/s12885-022-09619-9 |
Ejemplares similares
-
SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2
por: Masuo, Kenji, et al.
Publicado: (2021) -
Inhibition of dopamine receptor D1 signaling promotes human bile duct cancer progression via WNT signaling
por: Yogo, Akitada, et al.
Publicado: (2022) -
Time–frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer
por: Sato, Asahi, et al.
Publicado: (2020) -
Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study
por: Masui, Toshihiko, et al.
Publicado: (2023) -
Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
por: Masui, Toshihiko, et al.
Publicado: (2022)